Grundinformationen
- Standard-SMILES
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+]- InChIKey
WJSIUCDMWSDDCE-UHFFFAOYSA-K- Summenformel
- C6H5Li3O7
- Durchschnittliche Molmasse
- 210 g/mol
- Monoisotopische Masse
- 210,05154115
Überblick
Lithium Citrate can cause developmental toxicity according to state or federal government labeling requirements.
Namen und Bezeichner
- Bevorzugter Name
- Lithium Citrate
- IUPAC
- trilithium;2-hydroxypropane-1,2,3-tricarboxylate
- Lokaler Name
- Zitronensure, Lithiumsalz
- Englischer Name
- citric acid, lithium salt
- Summenformel
- C6H5Li3O7
- Molmasse
- 209.9227
Namen und Synonyme
Lithium citrateLitarexCITRIC ACID, TRILITHIUM SALTLithium Citrate (anhydrous)anhydrous lithium citrateCHEBI:64735Lithium (as citrate)CHEBI:64754NSC-758700Li-liquidRefChem:55514trilithium(1+) 2-hydroxypropane-1,2,3-tricarboxylate
Weitere Namen anzeigen
Einecs 233-819-9citric acid, lithium salt2-Hydroxy-1,2,3-propanetricarboxylic acid/lithium,(1:x) salt
5Z6E9K79YVLithonate S919-16-4Trilithium citrateCitric acid trilithium saltLithium citrate anhydrousLithium (Citrate)1,2,3-Propanetricarboxylic acid, 2-hydroxy-, trilithium salt
Datenbank-Bezeichner
- CAS
10377-38-5、313222-91-2、6080-58-6、919-16-4- PubChem CID
- 13520
- DTXSID
DTXSID70883185- ChEMBL
CHEMBL1201170、CHEMBL2103738- ChEBI
CHEBI:64735- UNII
- 3655633623
- EC Number
- 213-045-8、233-819-9、612-032-8、684-184-3
- Nikkaji
- J48.475J
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 141 Ų
- H-Brücken-Donoren
- 1
- H-Brücken-Akzeptoren
- 7
- Frei drehbare Bindungen
- 2
- Schwere Atome
- 16
- Formalladung
- 0
- Komplexität
- 211
Experimentelle und physikochemische Eigenschaften
Chemical ClassesMetals -> Organic Acids, Metal Salts
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Physical DescriptionTetrahydrate: White deliquescent solid; [Merck Index]
Sicherheit und Regulatorisches
GHS-Klassifizierung
GHS Classification
Warning
H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
P264+P265, P280, P305+P351+P338, and P337+P317 (click each P-code to see the statement)
Aggregated GHS information provided per 38 reports by companies from 1 notifications to the ECHA C&L Inventory.
This chemical does not meet GHS hazard criteria for 96.4% (27 of 28) of all reports.
Not Classified
Gefahrenhinweise
Regulatory Information
Chemical: 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, trilithium salt
Hazard Traits - Developmental Toxicity
Status: Active Update: 23-05-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/22333
Lithium citrate: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, trilithium salt: Human health tier I assessment
Hazards SummaryMay cause eye irritation; [GFS Chemicals MSDS] See Lithium.
Hazard Classes and Categories
Not Classified
Eye Irrit. 2 (100%)
Sicherheit und Schutzausrüstung
Exposure Control and Personal Protection0.2 [mg/m3], inhalable fraction, as Li[German Research Foundation (DFG)]
Toxikologische Informationen
Adverse EffectsNeurotoxin - Other CNS neurotoxin
Chemie und Industrie
Pharmakologische Informationen
Pharmacodynamics
Although lithium has been used for over 50 years in treatment of bipolar disorder, the mechanism of action is still unknown. Lithium's therapeutic action may be due to a number of effects, ranging from inhibition of enzymes such as glycogen synthase kinase 3, inositol phosphatases, or modulation of glutamate receptors.
Mechanism of Action
The precise mechanism of action of Li+ as a mood-stabilizing agent is currently unknown. It is possible that Li+ produces its effects by interacting with the transport of monovalent or divalent cations in neurons. An increasing number of scientists have come to the conclusion that the excitatory neurotransmitter glutamate is the key factor in understanding how lithium works. Lithium has been shown to change the inward and outward currents of glutamate receptors (especially GluR3), without a shift in reversal potential. Lithium has been found to exert a dual effect on glutamate receptors, acting to keep the amount of glutamate active between cells at a stable, healthy level, neither too much nor too little. It is postulated that too much glutamate in the space between neurons causes mania, and too little, depression. Another mechanism by which lithium might help to regulate mood include the non-competitive inhibition of an enzyme called inositol monophosphatase. Alternately lithium's action may be enhanced through the deactivation of the GSK-3B enzyme. The regulation of GSK-3B by lithium may affect the circadian clock. GSK-3 is known for phosphorylating and thus inactivating glycogen synthase. GSK-3B has also been implicated in the control of cellular response to damaged DNA. GSK-3 normally phosphorylates beta catenin, which leads to beta catenin degratation. When GSK-3 is inhibited, beta catenin increases and transgenic mice with overexpression of beta catenin express similar behaviour to mice treated with lithium. These results suggest that increase of beta catenin may be a possible pathway for the therapeutic action of lithium.
FDA Pharmacological Classification
LITHIUM CITRATE
Mood Stabilizer [EPC]
Verwendung und Herstellung
UsesUsed as an antidepressant; [Merck Index]
General Manufacturing Information1,2,3-Propanetricarboxylic acid, 2-hydroxy-, lithium salt (1:3): ACTIVE
Anbieter1 Anbieter
陕西缔都新材料有限公司029-63373950 17392216152 · [email protected]
Zugehörige Reaktionen
8
Verknüpfte Notizen
Wird geladen…